Reports
Diabetes and high blood pressure generics in Europe
Generics contribute value to the European Union (EU), according to a presentation by Mr Victor Lino Mendonça given at the International Generic Pharmaceutical Alliance (IGPA)’s 16th Annual Conference, which was held in Brussels, Belgium, 9–11 December 2013 [1].
The Brazilian generics market
Generics are an effective tool to provide affordable, safe and reliable medicines to patients in Brazil, according to a presentation by Telma Salles [1].
The generics market in Taiwan
Taiwan is a growing market for pharmaceuticals and the generics market is becoming more competitive in terms of price and quality, according to a presentation by Yi-Yun Wang [1].
The generics market in India
The profitability of generics companies in India is under pressure, according to a presentation by Mr Alok Sonig [1].
Cost savings and use of generics in Europe
Generics provide significant savings for the healthcare systems, as well as increased access to medicines, in the European Union (EU). This is according to a presentation by Mr Victor Lino Mendonça given at the International Generic Pharmaceutical Alliance (IGPA)’s 16th Annual Conference, which was held in Brussels, Belgium, 9-11 December 2013 [1].
FDA’s labelling proposal will increase cost of generics
In November 2013 the US Food and Drug Administration (FDA) proposed a new rule which would allow generics makers to change their labelling in the same way as brand-name manufacturers [1]. However, an analysis by economic consulting firm Matrix Global Advisors (MGA) shows that this change would add US$4 billion to the annual healthcare costs in the US.
Generics save US 1.2 trillion over last 10 years
Generics have saved consumers and the US healthcare system US$217 billion in 2012 and have saved the US in excess of US$1.2 trillion between 2003 and 2012, according to a report by the Generic Pharmaceutical Association (GPhA) [1].
Biosimilars: what physicians need to know
A biosimilar is a medicinal product that is similar to a biological medicinal product that has already been authorized. Biologicals are comprised of proteins, such as hormones (growth hormones, insulins, erythropoietins), enzymes, that are naturally produced in the human body, or monoclonal antibodies. Biologicals are derived through three main sources: yeast cells, bacterial cells and mammalian cells.
Giving EU Member States more freedom could increase early access to new drugs
A UK report urges giving European Union (EU) Member States greater freedoms to determine their own policies with respect to data protection and early access to medical innovations [1].
EU problematic patent settlements remain at low level
The European Commission’s (EC) fourth monitoring exercise of patent settlements in the pharmaceutical sector has shown the number of potentially problematic settlements under EU antitrust rules remain at a low level. This finding comes despite the fact that the overall number of patent settlements has increased compared to the previous monitoring periods. The EC takes this as evidence that companies can successfully settle patent disputes within the boundaries of the European Union (EU) antitrust rules.
